Infliximab as a Second‐Line Therapy for Children with Refractory Kawasaki Disease; A Systematic Review and Meta‐analysis of Randomized Controlled Trials

Suad Kabbaha,Alyssa Milano,Mamoon A. Aldeyab,Kristian Thorlund

British Journal of Clinical Pharmacology（2022）

引用 2|浏览3

暂无评分

摘要

Moderate-certainty evidence indicates that infliximab may reduce the incidence of treatment resistance in children with refractory KD. However, the limited strength of evidence warrants further research.

查看译文

关键词

coronary artery aneurysms,infliximab,randomized controlled trials,refractory Kawasaki disease,systematic review,treatment resistance,tumour necrosis factor-alpha inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要